Atlas Trials

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical trial NCT01718353 · COMPLETED

Trial details

NCT number
NCT01718353
Sponsor
Sanofi
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Prostate Cancer Metastatic
Start date
2013-03-01
Primary completion
2015-08-01
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.